Drug Trial Radar · NCT00486889
Growth and Development Study of Alglucosidase Alfa
Last checked: Nov 20, 2026Latest source record: Aug 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 26, 2008
Primary completion
Nov 23, 2021
Study completion Nov 23, 2021
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pompe disease (also known as glycogen storage disease Type II) is a rare autosomal recessive metabolic muscle disease caused by the deficiency of acid α glucosidase (GAA), an enzyme that degrades lysosomal glycogen. As opposed to the exclusively cytoplasmic accumulation of glycogen that occurs in other glycogen storage disorders, Pompe disease is characterized by organelle bound (lysosomal) and extra-lysosomal accumulation of glycogen in many body tissues, ultimately leading to multisystemic pathology. The overall objective of this study was to evaluate the long-term growth and development of participants with infantile-onset Pompe disease with alglucosidase alfa before 1 year of age. Participants were to be followed for a 10-year period.
Conditions
- Pompe Disease
- Glycogen Storage Disease Type II (GSD-II)
- Acid Maltase Deficiency Disease
Interventions
alglucosidase alfaBiological
Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recumbent Height/Length of Participants in Centimeters (cm)Time frame: Participants 1-12:Baseline, Participant1: Wk 52, Participant2: Wk82, Participants 3-4: Wk208, Participant5: Wk12, Participant6: Wk365, Participant7: Wk64, Participant8:Wk156, Participant9:Wk364, Participant10:Wk52, Participant11:Wk156, Participant12:Wk520
- Body Weight of Participants in Kilograms (kg)Time frame: Participant1-12:Baseline, Participant1:Wk 52, Participant2:Wk82, Participant3: Wk208,Participant4:Wk364,Participant5:Wk12,Participant6:Wk365,Participant7:Wk64,Participant8:Wk156,Participant9:Wk364,Participant10:Wk52,Participant11:Wk156,Participant12:Wk520
- Head Circumference of Participants in Centimeters (cm)Time frame: Participants1-12:Baseline, Participant1:Week(Wk)52, Participant2:Wk82, Participants3and4:Wk208, Participant5:Wk12, Participant6:Wk365, Participant7:Wk64, Participant8:Wk156, Participant9:Wk312, Participant10:Wk52, Participant11:Wk156, Participant12:Wk468
- Motor Subscale of Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) Normative Composite ScoresTime frame: Participants 1-12: Baseline, Participant-1: Week 52, Participant-2: Week 83, Participants 3 and 4: Week 104, Participant-6: Week 78, Participants 7 and 8: Week 26, Participant-9: Week 156, Participants 10 and 11: Week 26, Participant-12: Week 104
- Gross Motor Function Measure (GMFM-88) Total ScoresTime frame: Participants 1-12: Baseline, Participants 1 and 2: Wk 52, Participants 3 and 4: Wk 208, Participant-6: Wk 359, Participant-7: Wk 26, Participant-8: Wk 156, Participant-9: Wk 312, Participant-11: Wk 156, Participant-12: Wk416
- Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) Scaled ScoresTime frame: Participants1-12:Baseline, Participants 1 and 2: Wk 52, Participants 3 and 4: Wk 208, Participant-6: Wk 359, Participant-7: Wk 52, Participant-8: Wk156, Participant-9: Wk 312, Participant-10: Wk 26, Participant-11: Wk 156, Participant-12: Wk 416
- Cognitive and Language Subscales of Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) Normative Composite ScoresTime frame: Participants 1-12: Baseline, Participant-1: Week 52, Participant-2: Week 83, Participants 3 and 4: Week 104, Participant-6: Week 78, Participants 7 and 8: Week 26, Participant-9: Week 156, Participants 10 and 11:Week 26, Participant-12: Week 104
- Brief Intelligence Quotient (IQ) Score of the Leiter International Performance Scale-Revised (Leiter-R)Time frame: Participants 1 and 2: Week 156, Participant-3: Week 260, Participant-4: Week 156, Participant-5: Week 208
- Nonverbal Intelligence Quotient (IQ) Score of Leiter International Performance Scale - 3rd Edition (Leiter-3)Time frame: Participant-1: Week 156, Participant-2: Week 312, Participant-3: Week 416
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Gainesville, Florida
Site not named
Decatur, Georgia
Site not named
Detroit, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.